The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 36, No. 3, pp. 440-443. DOI 10.1345/aph.1A241
© 2002 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reeves, R.
Right arrow Articles by Beddingfield, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reeves, R.
Right arrow Articles by Beddingfield, J.

Research Articles

Neurotoxic syndrome associated with risperidone and fluvoxamine

RR Reeves, JE Mack, and JJ Beddingfield

OBJECTIVE: To report a case of a neurotoxic syndrome in a patient undergoing concomitant treatment with risperidone and fluvoxamine. CASE REPORT: A 24-year-old African American woman hospitalized for psychosis was unresponsive to risperidone. Because of obsessive symptoms, low doses of fluvoxamine were added to her treatment regimen. Within 2 days, she developed confusion, diaphoresis, diarrhea, hyperreflexia, and myoclonus, which then progressed to rigidity, fever, and unresponsiveness, requiring endotracheal intubation. Symptoms resolved over 10 days with discontinuation of medication, hydration, and bromocriptine 5 mg 3 times daily. Ultimately, she was treated with olanzapine and fluvoxamine without adverse effects. DISCUSSION: This represents the first reported case of a neurotoxic syndrome secondary to treatment with risperidone and fluvoxamine. Differential diagnosis between neuroleptic malignant syndrome (NMS) and serotonin syndrome (SS) could not be accurately determined because of the overlap of signs and symptoms of both syndromes. NMS and SS may represent different aspects of a more generalized neurotoxic syndrome. This could be an important consideration in formulating treatment for neurotoxic syndromes. CONCLUSIONS: Clinicians should be aware of potentially serious adverse reactions that may occur during concomitant treatment with antipsychotics and selective serotonin-reuptake inhibitors.


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
D. L Stevens
Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome
Ann. Pharmacother., September 1, 2008; 42(9): 1290 - 1297.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
S. H. Preskorn
Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future.
J Psychopharmacol, July 1, 2006; 20(4 Suppl): 85 - 94.
[Abstract] [PDF]

Home page
 J Am Psychiatr Nurses AssocHome page
L. H. Beebe
Health Promotion in Persons with Schizophrenia: Atypical Medications
Journal of the American Psychiatric Nurses Association, August 1, 2003; 9(4): 115 - 122.
[Abstract] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2002 by Harvey Whitney Books Company.